Amanzhan Abubakirov

Also affiliated with Université de Montpellier, Sorbonne Université, Laboratoire National de Référence, Kazakh Institute of Oncology and Radiology, Centre d'Immunologie et des Maladies Infectieuses, Saint-Petersburg Research Institute of Phthisiopulmonology, Ministry of Justice of the Republic of Kazakhstan

MedicinePharmacology, Toxicology and PharmaceuticsImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial”.

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(25)00194-8

N/A

0.781DataRank · unranked

26 citations

Uzma Khan, Gustavo E. Velásquez, Maëlenn Gouillou, Muhammad Hammad Ali, Samreen Amjad +95 more